<DOC>
	<DOC>NCT01690390</DOC>
	<brief_summary>The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that achieve stable disease after 8 weeks routine therapy.</brief_summary>
	<brief_title>Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease</brief_title>
	<detailed_description>This is a multi-center phase II randomized controlled study to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that achieve stable disease after 8 weeks routine therapy by PFS, as well as OS and DCR. The adverse events and adverse reaction are evaluated as well.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients confirmed by sputum cytology) No previous targeted treatment such as gefitinib, erlotinib. With a measurable disease(longest diameters &gt;=10mm with Spiral computed tomography (CT)and &gt;=20mm with conventional CT) at least according to RECIST Criteria WHO performance status(PS)&lt;= 2 N&gt;=1.5×109/L, Plt&gt;=1.0×109/L,Hb&gt;=10g/dL;AST&amp;ALT should &lt;3ULN(without liver metastasis) or &lt;5ULN(with liver metastasis).TBIL&lt;=1.5ULN. Signed and dated informed consent before the start of specific protocol procedures. Allergic to icotinib Patients with metastatic brain tumors with symptoms. Experience of AntiEGFR(the epidermal growth factor receptor) Monoclonal Antibody or small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab. Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>